Overview

Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This open-label extension study will allow subjects who have completed either the 3242K1-2000-WW or 3242K1-2001-JA study to receive up to an additional 48 weeks of ATN-103 treatment and will provide data on the long-term safety and tolerability of ATN-103 in subjects with rheumatoid arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Ablynx